PMCC Staff Publications

pmcc logo sml

 

 Here are the staff publications for August 2022.

Compiled by the Health Sciences Library (RMH, RWH, PMCC & Victorian Mental Health) 5th September 2022.

 

1. Averbuch D, De Greef J, Dureault A, Wendel L, Tridello G, Lebeaux D, Mikulska M, Gil L, Knelange N, Zuckerman T, Roussel X, Robin C, Xhaard A, Aljurf M, Beguin Y, Le Bourgeois A, Botella-Garcia C, Khanna N, Van Praet J, Kroger N, Blijlevens N, Ducastelle Lepretre S, Ho A, Roos-Weil D, Yeshurun M, Lortholary O, Fontanet A, de la Camara R, Coussement J, Maertens J, Styczynski J, European Study Group for Nocardia in Hematopoietic Cell T. Nocardia Infections in Hematopoietic Cell Transplant Recipients: A Multicenter International Retrospective Study of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation. Clin Infect Dis 2022;75:88-97.

2. Azad AA, Tran B, Davis ID, Parente P, Evans M, Wong S, Brown S, Evans S, Millar J, Murphy DG, Papa N. Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer. Intern Med J 2022;52:1339-46.

3. Beaumont S, Angel CM, Dawson SJ. Denosumab and invasive cervical root resorption: a case report. Aust Dent J 2022;67:183-9.

4. Bolton D, Hong A, Papa N, Perera M, Kelly B, Duncan C, Clouston D, Lawrentschuk N. Cribriform pattern disease over-represented in pelvic lymph node metastases identified on (68)GA PSMA-PET/CT. BJUI Compass 2022;3:371-6.

5. Bonney A, Malouf R, Marchal C, Manners D, Fong KM, Marshall HM, Irving LB, Manser R. Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality. Cochrane Database Syst Rev 2022;8:Cd013829.

6. Bucknell NW, Belderbos J, Palma DA, Iyengar P, Samson P, Chua K, Gomez D, McDonald F, Louie AV, Faivre-Finn C, Hanna GG, Siva S, International Association for the Study of Lung Cancer Advanced Radiation Technology C. Avoiding Toxicity With Lung Radiation Therapy: An IASLC Perspective. J Thorac Oncol 2022;17:961-73.

7. Cabalag CS, Yates M, Corrales MB, Yeh P, Wong SQ, Zhang BZ, Fujihara KM, Chong L, Hii MW, Dawson SJ, Phillips WA, Duong CP, Clemons NJ. Potential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal Adenocarcinoma. Ann Surg 2022;276:e120-e6.

8. Ceder S, Eriksson SE, Liang YY, Cheteh EH, Zhang SM, Fujihara KM, Bianchi J, Bykov VJN, Abrahmsen L, Clemons NJ, Nordlund P, Rudd SG, Wiman KG. Correction: Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells. Cell Death Dis 2022;13:672.

9. Chen K, Ong S, Lawrentschuk N. Biomarkers Accurately Inform Treatment Decisions in Localised Prostate Cancer. Eur Urol Focus 2022;8:643-5.

10. Choy KT, Lam K, Kong JC. Exercise and colorectal cancer survival: an updated systematic review and meta-analysis. Int J Colorectal Dis 2022;37:1751-8.

11. Chua BH, Link EK, Kunkler IH, Whelan TJ, Westenberg AH, Gruber G, Bryant G, Ahern V, Purohit K, Graham PH, Akra M, McArdle O, O'Brien P, Harvey JA, Kirkove C, Maduro JH, Campbell ID, Delaney GP, Martin JD, Vu TTT, Muanza TM, Neal A, Olivotto IA. Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study. Lancet 2022;400:431-40.

12. Copaescu AM, James F, Vogrin S, Rose M, Chua K, Holmes NE, Turner NA, Stone C, Phillips E, Trubiano J. Use of a penicillin allergy clinical decision rule to enable direct oral penicillin provocation: an international multicentre randomised control trial in an adult population (PALACE): study protocol. BMJ Open 2022;12:e063784.

13. Crake RLI, Burgess ER, Wiggins GAR, Magon NJ, Das AB, Vissers MCM, Morrin HR, Royds JA, Slatter TL, Robinson BA, Phillips E, Dachs GU. Ascorbate content of clinical glioma tissues is related to tumour grade and to global levels of 5-hydroxymethyl cytosine. Sci Rep 2022;12:14845.

14. Cremona M, Vandenberg CJ, Farrelly AM, Madden SF, Morgan C, Kalachand R, McAlpine JN, Toomey S, Huntsman DG, Grogan L, Breathnach O, Morris P, Carey MS, Scott CL, Hennessy BT. BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors. Br J Cancer 2022;127:488-99.

15. Cristofanilli M, Rugo HS, Im SA, Slamon DJ, Harbeck N, Bondarenko I, Masuda N, Colleoni M, DeMichele A, Loi S, Iwata H, O'Leary B, Andre F, Loibl S, Bananis E, Liu Y, Huang X, Kim S, Lechuga Frean MJ, Turner NC. Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. Clin Cancer Res 2022;28:3433-42.

16. Cucanic O, Farnsworth RH, Stacker SA. The cellular and molecular mediators of metastasis to the lung. Growth Factors 2022;40:119-52.

17. Czosnek L, Zopf EM, Cormie P, Rosenbaum S, Richards J, Rankin NM. Developing an implementation research logic model: using a multiple case study design to establish a worked exemplar. Implement Sci Commun 2022;3:90.

18. de Latour RP, Szer J, Weitz IC, Röth A, Höchsmann B, Panse J, Usuki K, Griffin M, Kiladjian JJ, de Castro CM, Nishimori H, Ajayi T, Al-Adhami M, Deschatelets P, Francois C, Grossi F, Risitano AM, Hillmen P. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. Lancet Haematol 2022;9:e648-e59.

19. Dolzhenko E, Weisburd B, Ibañez K, Rajan-Babu IS, Anyansi C, Bennett MF, Billingsley K, Carroll A, Clamons S, Danzi MC, Deshpande V, Ding J, Fazal S, Halman A, Jadhav B, Qiu Y, Richmond PA, Saunders CT, Scheffler K, van Vugt J, Zwamborn R, Chong SS, Friedman JM, Tucci A, Rehm HL, Eberle MA. REViewer: haplotype-resolved visualization of read alignments in and around tandem repeats. Genome Med 2022;14:84.

20. Dowling MR, Dickinson M. Post CAR-T cytopenia: poorly understood and clinically challenging. Leuk Lymphoma 2022;63:1774-6.

21. Fogarty T, Tacey M, McCorkell G, Kok D, Hornby C, Milne RL, Millar J, Foroudi F, Ong WL. Patterns of the use of advanced radiation therapy techniques for the management of bone metastases and the associated factors in Victoria. J Med Imaging Radiat Oncol 2022;66:678-87.

22. Gates P, Krishnasamy M, Wilson C, Hawkes EA, Doré V, Perchyonok Y, Rowe CC, Walker AK, Vardy JL, de Ruiter MB, Cushion T, Dhillon HM, Gough K. Cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma undergoing standard chemotherapy: a longitudinal feasibility study. Support Care Cancer 2022;30:7731-43.

23. Grogan A, Loveday B, Michael M, Wong HL, Gibbs P, Thomson B, Lee B, Ko HS. Real-world staging computed tomography scanning technique and important reporting discrepancies in pancreatic ductal adenocarcinoma. ANZ J Surg 2022;92:1789-96.

24. Grootes I, Keeman R, Blows FM, Milne RL, Giles GG, Swerdlow AJ, Fasching PA, Abubakar M, Andrulis IL, Anton-Culver H, Beckmann MW, Blomqvist C, Bojesen SE, Bolla MK, Bonanni B, Briceno I, Burwinkel B, Camp NJ, Castelao JE, Choi JY, Clarke CL, Couch FJ, Cox A, Cross SS, Czene K, Devilee P, Dörk T, Dunning AM, Dwek M, Easton DF, Eccles DM, Eriksson M, Ernst K, Evans DG, Figueroa JD, Fink V, Floris G, Fox S, Gabrielson M, Gago-Dominguez M, García-Sáenz JA, González-Neira A, Haeberle L, Haiman CA, Hall P, Hamann U, Harkness EF, Hartman M, Hein A, Hooning MJ, Hou MF, Howell SJ, Ito H, Jakubowska A, Janni W, John EM, Jung A, Kang D, Kristensen VN, Kwong A, Lambrechts D, Li J, Lubiński J, Manoochehri M, Margolin S, Matsuo K, Taib NAM, Mulligan AM, Nevanlinna H, Newman WG, Offit K, Osorio A, Park SK, Park-Simon TW, Patel AV, Presneau N, Pylkäs K, Rack B, Radice P, Rennert G, Romero A, Saloustros E, Sawyer EJ, Schneeweiss A, Schochter F, Schoemaker MJ, Shen CY, Shibli R, Sinn P, Tapper WJ, Tawfiq E, Teo SH, Teras LR, Torres D, Vachon CM, van Deurzen CHM, Wendt C, Williams JA, Winqvist R, Elwood M, Schmidt MK, García-Closas M, Pharoah PDP. Incorporating progesterone receptor expression into the PREDICT breast prognostic model. Eur J Cancer 2022;173:178-93.

25. Gruber E, So J, Lewis AC, Franich R, Cole R, Martelotto LG, Rogers AJ, Vidacs E, Fraser P, Stanley K, Jones L, Trigos A, Thio N, Li J, Nicolay B, Daigle S, Tron AE, Hyer ML, Shortt J, Johnstone RW, Kats LM. Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells. Cell Rep 2022;40:111182.

26. Hall VG, Humar A, Kumar D. Utility of Cytomegalovirus Cell-Mediated Immunity Assays in Solid Organ Transplantation. J Clin Microbiol 2022;60:e0171621.

27. Higgins MJ, Alipour R, Pope K, Ung KA, Kok DL, Chua MS. QUAD SHOT Radiotherapy and Doublet Immunotherapy in the Management of Anal Mucosal Melanoma: A Case Series of Efficacy and Toxicity of a Novel Treatment Approach and a Review of the Literature. Clin Colorectal Cancer 2022;21:e179-e86.

28. Holmes Z, Courtney A, Hiong A. Haemophagocytic lymphohistiocytosis as a complication of combination anti-PD-1 and anti-CTLA-4 checkpoint inhibitor immunotherapy for metastatic melanoma, and the outcome of rechallenge with single-agent anti-PD-1 immunotherapy. BMJ Case Rep 2022;15.

29. Islam Roney MMS, Lanagan MC, Sheng Y, Gough MM, Snell C, Nguyen NT, Lawler K, Liu C, Lam AK, Kijanka GS. Isotypic analysis of anti-p53 serum autoantibodies and p53 protein tissue phenotypes in colorectal cancer. Hum Pathol 2022;128:1-10.

30. Jaeger U, Tam CS, Borchmann P, McGuirk JP, Johansen M, Waller EK, Jaglowski S, Andreadis C, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Salles G, Schuster SJ, He F, Maziarz RT, Mayer S, Makita S, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Goto H, Colicino S, Agarwal A, Lobetti-Bodoni C, Bishop MR. Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma. Blood Adv 2022;6:4816-20.

31. James F, Goh MSY, Mouhtouris E, Vogrin S, Chua KYL, Holmes NE, Awad A, Copaescu AM, De Luca JF, Zubrinich C, Gin D, Cleland H, Douglas A, Kern JS, Katelaris CH, Thien F, Barnes S, Yun J, Tong W, Smith WB, Carr A, Anderson T, Legg A, Bourke J, Mackay LK, Aung AK, Phillips EJ, Trubiano J. Study protocol: Australasian Registry of Severe Cutaneous Adverse Reactions (AUS-SCAR). BMJ Open 2022;12:e055906.

32. Jangholi A, Müller Bark J, Kenny L, Vasani S, Rao S, Dolcetti R, Punyadeera C. Exosomes at the crossroad between therapeutic targets and therapy resistance in head and neck squamous cell carcinoma. Biochim Biophys Acta Rev Cancer 2022;1877:188784.

33. Jiang W, Clancy LE, Avdic S, Sutrave G, Street J, Simms R, McGuire HM, Patrick E, Chan AS, McCaughan G, Myers N, Micklethwaite KP, Antonenas V, Selim AG, Ritchie D, Bateman CM, Shaw PJ, Blyth E, Gottlieb DJ. Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant. Blood Adv 2022;6:4949-66.

34. Jobson D, Roffey B, Arnold C, Azzi A, Button-Sloan A, Dawson T, Fernandez-Penas P, Fishburn P, Gyorki DE, Hiscutt EL, Jakrot V, Lilleyman A, Lochhead A, Long GV, Mailer S, Mann G, McCormack CJ, Muir J, Pratt GF, Scolyer RA, Shackelton M, Shumack S, Soyer HP, Tan CG, Webb A, Zalcberg J, Morton R, Mar V. Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry (MelCOR): A modified Delphi study. Australas J Dermatol 2022;63:344-51.

35. Key S, Chia C, Hasan Z, Sundaresan P, Dwivedi RC, Riffat F. Systematic review of prognostic factors in carcinoma ex pleomorphic adenoma. Oral Oncol 2022;133:106052.

36. Kim TW, Burris HA, de Miguel Luken MJ, Pishvaian MJ, Bang YJ, Gordon M, Awada A, Camidge DR, Hodi FS, McArthur GA, Miller WH, Cervantes A, Chow LQ, Lesokhin AM, Rutten A, Sznol M, Rishipathak D, Chen SC, Stefanich E, Pourmohamad T, Anderson M, Kim J, Huseni M, Rhee I, Siu LL. First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. Clin Cancer Res 2022;28:3452-63.

37. Kron T, Bressel M, Lonski P, Hill C, Mercieca-Bebber R, Ahern V, Lehman M, Johnson C, Latty D, Ward R, Miller D, Banjade D, Morriss D, De Abreu Lourenco R, Woodcock J, Montgomery R, Lehmann J, Chua BH. TROG 14.04: Multicentre Study of Feasibility and Impact on Anxiety of DIBH in Breast Cancer Patients. Clin Oncol (R Coll Radiol) 2022;34:e410-e9.

38. Lakhani A, Jamel W, Riddiough GE, Cabalag CS, Stevens S, Liu DS. Prophylactic negative pressure wound dressings reduces wound complications following emergency laparotomies: A systematic review and meta-analysis. Surgery 2022;172:949-54.

39. Lamberti MJ, Montico B, Ravo M, Nigro A, Giurato G, Iorio R, Tarallo R, Weisz A, Stellato C, Steffan A, Dolcetti R, Casolaro V, Faè DA, Dal Col J. Integration of miRNA:mRNA Co-Expression Revealed Crucial Mechanisms Modulated in Immunogenic Cancer Cell Death. Biomedicines 2022;10.

40. Lamkin DM, Chen S, Bradshaw KP, Xu S, Faull KF, Sloan EK, Cole SW. Low-dose exposure to PBDE disrupts genomic integrity and innate immunity in mammary tissue. Front Genet 2022;13:904607.

41. Lasocki A, McArthur GA. Correlation of MRI signal characteristics of intracranial melanoma metastases with BRAF mutation status. Melanoma Res 2022;32:373-8.

42. Lindeman GJ, Fernando TM, Bowen R, Jerzak KJ, Song X, Decker T, Boyle F, McCune S, Armstrong A, Shannon C, Bertelli G, Chang CW, Desai R, Gupta K, Wilson TR, Flechais A, Bardia A. VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results. Clin Cancer Res 2022;28:3256-67.

43. Lindsay J, Krantz EM, Morris J, Sweet A, Tverdek F, Joshi A, Yeh R, Hill JA, Greenwood M, Chen SC, Kong DCM, Slavin M, Pergam SA, Liu C. Voriconazole in Hematopoietic Stem Cell Transplantation and Cellular Therapies: Real-World Usage and Therapeutic Level Attainment at a Major Transplantation Center. Transplant Cell Ther 2022;28:511 e1- e10.

44. Lockie EB, Knowles B, Gill PK, Thomson B, Loveday BPT. Comparison of risk adjusted excess post-operative pancreatic fistula rates after pancreaticoduodenectomy using cumulative sum analysis. ANZ J Surg 2022;92:1784-8.

45. Martin FC, Conduit C, Loveland KL, Thomas B, Lewin J, Tran B. Genetics of testicular cancer: a review. Curr Opin Urol 2022;32:481-7.

46. McNamara N, Saunders E, Varghese S, Zheng R, Simpson K, Varma DM, Johnson MM, Hasan Zahid MS, Bachelder EM, Ainslie KM, No JH, Koh D, Shum D, Das N, Patra B, Roy J, Talukdar A, Ganguly D, McConville M, Baell J. Hit-to-lead optimization of novel phenyl imidazole carboxamides that are active against Leishmania donovani. Eur J Med Chem 2022;240:114577.

47. McQuilten Z, Wellard C, Moore E, Augustson B, Bergin K, Blacklock H, Harrison S, Ho PJ, King T, Quach H, Mollee P, Rosengarten B, Walker P, Wood E, Spencer A. Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). Br J Haematol 2022;198:830-7.

48. Mejía-Hernández JO, Raghu D, Caramia F, Clemons N, Fujihara K, Riseborough T, Teunisse A, Jochemsen AG, Abrahmsén L, Blandino G, Russo A, Gamell C, Fox SB, Mitchell C, Takano EA, Byrne D, Miranda PJ, Saleh R, Thorne H, Sandhu S, Williams SG, Keam SP, Haupt Y, Haupt S. Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status. Cancers (Basel) 2022;14.

49. Molica S, Tam C, Polliack A. Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia. Hematol Oncol 2022;40:313-9.

50. Nussing S, Miosge LA, Lee K, Olshansky M, Barugahare A, Roots CM, Sontani Y, Day EB, Koutsakos M, Kedzierska K, Goodnow CC, Russ BE, Daley SR, Turner SJ. SATB1 ensures appropriate transcriptional programs within naive CD8(+) T cells. Immunol Cell Biol 2022;100:636-52.

51. Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai W, Girardi M, Gru A, Guenova E, Hodak E, Hoppe R, Kempf W, Kim E, Lechowicz MJ, Ortiz-Romero P, Papadavid E, Quaglino P, Pittelkow M, Prince HM, Sanches JA, Sugaya M, Vermeer M, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick J. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood 2022;140:419-37.

52. Oo HP, Pasricha SR, Thompson B, Winship I, Scardamaglia L. Rivaroxaban in the treatment of TEK-related venous malformation. Australas J Dermatol 2022;63:e255-e8.

53. Owen D, Siva S, Salama JK, Robinson C, Kruser TJ, Giuliani M. If at First You Don't Succeed-Stereotactic Body Radiation Therapy for Recurrent Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2022;114:5-9.

54. Pirie K, Traer E, Finniss D, Myles PS, Riedel B. Current approaches to acute postoperative pain management after major abdominal surgery: a narrative review and future directions. Br J Anaesth 2022;129:378-93.

55. Quek LE, van Geldermalsen M, Guan YF, Wahi K, Mayoh C, Balaban S, Pang A, Wang Q, Cowley MJ, Brown KK, Turner N, Hoy AJ, Holst J. Glutamine addiction promotes glucose oxidation in triple-negative breast cancer. Oncogene 2022;41:4066-78.

56. Ramsay RG, Flood M. New insights into the unique nature of colorectal cancer peritoneal metastases-rethinking HIPEC. Br J Cancer 2022;127:377-8.

57. Rathmell WK, Rumble RB, Van Veldhuizen PJ, Al-Ahmadie H, Emamekhoo H, Hauke RJ, Louie AV, Milowsky MI, Molina AM, Rose TL, Siva S, Zaorsky NG, Zhang T, Qamar R, Kungel TM, Lewis B, Singer EA. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. J Clin Oncol 2022;40:2957-95.

58. Reck M, Mok TSK, Mansfield A, De Boer R, Losonczy G, Sugawara S, Dziadziuszko R, Krzakowski M, Smolin A, Hochmair M, Garassino MC, de Castro Junior G, Bischoff H, Lam S, Cardona A, Morris S, Liu SV. Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide. J Thorac Oncol 2022;17:1122-9.

59. Riedel B, Dubowitz J, Yeung J, Jhanji S, Kheterpal S, Avidan MS. On the horns of a dilemma: choosing total intravenous anaesthesia or volatile anaesthesia. Br J Anaesth 2022;129:284-9.

60. Rinott Mizrahi G, Williams I, Azad A, Lawrentschuk N. Genetics of neuroendocrine prostate cancer: recent progress in genetic understanding is translating into therapeutic opportunities. Curr Opin Urol 2022;32:462-5.

61. Rischin D, Mehanna H, Young RJ, Bressel M, Dunn J, Corry J, Soni P, Fulton-Lieuw T, Iqbal G, Kenny L, Porceddu S, Wratten C, Robinson M, Solomon BJ, Trans-Tasman Radiation Oncology G, the De EHPVTG. Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103(+) immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomized trials. Ann Oncol 2022;33:804-13.

62. Santucci J, Tacey M, Thomson B, Michael M, Wong R, Shapiro J, Jennens R, Clarke K, Pattison S, Burge M, Zielinski R, Nikfarjam M, Ananda S, Lipton L, Gibbs P, Lee B. Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry. Eur J Cancer 2022;174:102-12.

63. Savas P, Lo LL, Luen SJ, Blackley EF, Callahan J, Moodie K, van Geelen CT, Ko YA, Weng CF, Wein L, Silva MJ, Bujak AZ, Yeung MM, Ftouni S, Hicks RJ, Francis PA, Lee CK, Dawson SJ, Loi S. Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study. Cancer Discov 2022;12:2058-73.

64. Schmitt AM, Spain L, Larkin J. Hitting the sweet spot: optimal use of corticosteroids for immune checkpoint inhibitor side-effects. Lancet Oncol 2022;23:1123-4.

65. Seymour JF, Kipps TJ, Eichhorst BF, D'Rozario J, Owen CJ, Assouline S, Lamanna N, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Mellink C, Chyla B, Panchal A, Lu T, Wu JQ, Jiang Y, Lefebure M, Boyer M, Kater AP. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood 2022;140:839-50.

66. Smith S, Brand M, Harden S, Briggs L, Leigh L, Brims F, Brooke M, Brunelli VN, Chia C, Dawkins P, Lawrenson R, Duffy M, Evans S, Leong T, Marshall H, Patel D, Pavlakis N, Philip J, Rankin N, Singhal N, Stone E, Tay R, Vinod S, Windsor M, Wright GM, Leong D, Zalcberg J, Stirling RG. Development of an Australia and New Zealand Lung Cancer Clinical Quality Registry: a protocol paper. BMJ Open 2022;12:e060907.

67. Souza-Fonseca-Guimaraes F, Rossi GR, Dagley LF, Foroutan M, McCulloch TR, Yousef J, Park HY, Gunter JH, Beavis PA, Lin CY, Hediyeh-Zadeh S, Camilleri T, Davis MJ, Huntington ND. TGFbeta and CIS Inhibition Overcomes NK-cell Suppression to Restore Antitumor Immunity. Cancer Immunol Res 2022;10:1047-54.

68. Souza-Fonseca-Guimaraes F, Rossi GR, Dagley LF, Foroutan M, McCulloch TR, Yousef J, Park HY, Gunter JH, Beavis PA, Lin CY, Hediyeh-Zadeh S, Camilleri T, Davis MJ, Huntington ND. TGFβ and CIS Inhibition Overcomes NK-cell Suppression to Restore Antitumor Immunity. Cancer Immunol Res 2022;10:1047-54.

69. Stewart GD, Klatte T, Cosmai L, Bex A, Lamb BW, Moch H, Sala E, Siva S, Porta C, Gallieni M. The multispeciality approach to the management of localised kidney cancer. Lancet 2022;400:523-34.

70. Tang JS, Varatharajah K, Hansa A, Choong PF. Extraskeletal myxoid chondrosarcoma: A rare but important differential of a retroperitoneal mass. J Med Imaging Radiat Oncol 2022;66:647-9.

71. Thompson D, Choo N, Bolton DM, Lawrentschuk N, Risbridger GP, Lawrence MG, Taylor RA. New approaches to targeting epigenetic regulation in prostate cancer. Curr Opin Urol 2022;32:472-80.

72. Thompson MC, Harrup RA, Coombs CC, Roeker LE, Pu JJ, Choi MY, Barr PM, Allan JN, Simkovic M, Leslie L, Rhodes J, Chong EA, Kamdar M, Skarbnik A, Lansigan F, McCall B, Saja K, Dyer MJS, Walter HS, Lefebure M, Thadani-Mulero M, Boyer M, Biondo J, Sail K, Manzoor BS, Furman R, Bantilan KS, Goy A, Feldman T, Labella D, Schuster SJ, Park J, Palomba L, Zelenetz A, Eyre TA, Kater AP, Seymour JF, Mato AR. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. Blood Adv 2022;6:4553-7.

73. Tran MJ, Jefford M, Smith B, Lynch F, Dhillon HM, Shaw J, McDowell L, White A, Halloran C, Wiesenfeld D, Ftanou M. Study protocol for the evaluation of Fear-Less: a stepped-care program for fear of cancer recurrence in survivors with early-stage disease. Pilot Feasibility Stud 2022;8:177.

74. van Dijk E, van Werkhoven E, Asher R, Mooi JK, Espinoza D, van Essen HF, van Tinteren H, van Grieken NCT, Punt CJA, Tebbutt NC, Ylstra B. Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX. Int J Cancer 2022;151:1166-74.

75. Waterland JL, Ismail H, Granger CL, Patrick C, Denehy L, Riedel B. Prehabilitation in high-risk patients scheduled for major abdominal cancer surgery: a feasibility study. Perioper Med (Lond) 2022;11:32.

76. Wong AK, Philip J, Wawryk O, Sabe MG, Yoong J, Everitt R, Mendis R, Chua J, Pisasale M, Le B. A Multi-Centre COVID-19 Study Examining Symptoms and Medication Use in the Final Week of Life. J Pain Symptom Manage 2022;64:e139-e47.

77. Xu W, Yang S, Tam CS, Seymour JF, Zhou K, Opat S, Qiu L, Sun M, Wang T, Trotman J, Pan L, Gao S, Zhou J, Zhou D, Zhu J, Song Y, Hu J, Feng R, Huang H, Su D, Shi M, Li J. Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies. Adv Ther 2022;39:4250-65.

78. Yeoh DK, Blyth CC, Kotecha RS. Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease. Br J Haematol 2022;198:887-92.

79. Zhu Z, Turner NC, Loi S, André F, Martin M, Diéras V, Gelmon KA, Harbeck N, Zhang C, Cao JQ, Yan Z, Lu DR, Wei P, VanArsdale TL, Rejto PA, Huang X, Rugo HS, Loibl S, Cristofanilli M, Finn RS, Liu Y. Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib. NPJ Precis Oncol 2022;6:56.